Afatinib

An overview of its clinical development in non-small-cell lung cancer and other tumors

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Afatinib is an oral, irreversible, tyrosine kinase inhibitor (TKI) of EGFR, HER2 and HER4. According to phase I studies, the recommended dose of afatinib was 50. mg daily. Rash, acne, diarrhea and stomatitis were the most common adverse events. Afatinib failed to demonstrate an improvement in overall survival in unselected heavily pretreated NSCLC patients (Lux-Lung-1). On the contrary, the Lux-Lung-3 and -6 trials met the primary end point, demonstrating a significant increase in terms of PFS with afatinib compared with chemotherapy in the first line treatment of EGFR mutant patients. Moreover, in both studies, afatinib improved overall survival in patients with exon 19 EGFR deletion (31.7 vs 20.7 months; HR: 0.59, p= 0.0001). The results of ongoing randomized trials should further clarify the efficacy of afatinib compared with first-generation TKIs in advanced NSCLC, its activity in the adjuvant and neoadjuvant settings, as well as its efficacy in other tumors.

Original languageEnglish
Pages (from-to)143-151
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Volume97
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Non-Small Cell Lung Carcinoma
Neoplasms
Lung
Stomatitis
Survival
Acne Vulgaris
Exanthema
Protein-Tyrosine Kinases
BIBW 2992
Exons
Diarrhea
Drug Therapy

Keywords

  • Afatinib
  • Clinical trials
  • EGFR
  • Head-neck
  • NSCLC

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

@article{89c2f7bf31c84a3cabcb7c3cc01e0b0d,
title = "Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors",
abstract = "Afatinib is an oral, irreversible, tyrosine kinase inhibitor (TKI) of EGFR, HER2 and HER4. According to phase I studies, the recommended dose of afatinib was 50. mg daily. Rash, acne, diarrhea and stomatitis were the most common adverse events. Afatinib failed to demonstrate an improvement in overall survival in unselected heavily pretreated NSCLC patients (Lux-Lung-1). On the contrary, the Lux-Lung-3 and -6 trials met the primary end point, demonstrating a significant increase in terms of PFS with afatinib compared with chemotherapy in the first line treatment of EGFR mutant patients. Moreover, in both studies, afatinib improved overall survival in patients with exon 19 EGFR deletion (31.7 vs 20.7 months; HR: 0.59, p= 0.0001). The results of ongoing randomized trials should further clarify the efficacy of afatinib compared with first-generation TKIs in advanced NSCLC, its activity in the adjuvant and neoadjuvant settings, as well as its efficacy in other tumors.",
keywords = "Afatinib, Clinical trials, EGFR, Head-neck, NSCLC",
author = "Pasqualina Giordano and Anna Manzo and Agnese Montanino and Raffaele Costanzo and Claudia Sandomenico and Piccirillo, {Maria Carmela} and Gennaro Daniele and Nicola Normanno and Guido Carillio and Gaetano Rocco and Roberto Bianco and Francesco Perrone and Alessandro Morabito",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.critrevonc.2015.08.016",
language = "English",
volume = "97",
pages = "143--151",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Afatinib

T2 - An overview of its clinical development in non-small-cell lung cancer and other tumors

AU - Giordano, Pasqualina

AU - Manzo, Anna

AU - Montanino, Agnese

AU - Costanzo, Raffaele

AU - Sandomenico, Claudia

AU - Piccirillo, Maria Carmela

AU - Daniele, Gennaro

AU - Normanno, Nicola

AU - Carillio, Guido

AU - Rocco, Gaetano

AU - Bianco, Roberto

AU - Perrone, Francesco

AU - Morabito, Alessandro

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Afatinib is an oral, irreversible, tyrosine kinase inhibitor (TKI) of EGFR, HER2 and HER4. According to phase I studies, the recommended dose of afatinib was 50. mg daily. Rash, acne, diarrhea and stomatitis were the most common adverse events. Afatinib failed to demonstrate an improvement in overall survival in unselected heavily pretreated NSCLC patients (Lux-Lung-1). On the contrary, the Lux-Lung-3 and -6 trials met the primary end point, demonstrating a significant increase in terms of PFS with afatinib compared with chemotherapy in the first line treatment of EGFR mutant patients. Moreover, in both studies, afatinib improved overall survival in patients with exon 19 EGFR deletion (31.7 vs 20.7 months; HR: 0.59, p= 0.0001). The results of ongoing randomized trials should further clarify the efficacy of afatinib compared with first-generation TKIs in advanced NSCLC, its activity in the adjuvant and neoadjuvant settings, as well as its efficacy in other tumors.

AB - Afatinib is an oral, irreversible, tyrosine kinase inhibitor (TKI) of EGFR, HER2 and HER4. According to phase I studies, the recommended dose of afatinib was 50. mg daily. Rash, acne, diarrhea and stomatitis were the most common adverse events. Afatinib failed to demonstrate an improvement in overall survival in unselected heavily pretreated NSCLC patients (Lux-Lung-1). On the contrary, the Lux-Lung-3 and -6 trials met the primary end point, demonstrating a significant increase in terms of PFS with afatinib compared with chemotherapy in the first line treatment of EGFR mutant patients. Moreover, in both studies, afatinib improved overall survival in patients with exon 19 EGFR deletion (31.7 vs 20.7 months; HR: 0.59, p= 0.0001). The results of ongoing randomized trials should further clarify the efficacy of afatinib compared with first-generation TKIs in advanced NSCLC, its activity in the adjuvant and neoadjuvant settings, as well as its efficacy in other tumors.

KW - Afatinib

KW - Clinical trials

KW - EGFR

KW - Head-neck

KW - NSCLC

UR - http://www.scopus.com/inward/record.url?scp=84952636827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952636827&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2015.08.016

DO - 10.1016/j.critrevonc.2015.08.016

M3 - Article

VL - 97

SP - 143

EP - 151

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -